Crosstalk between oxidative stress and epigenetic marks: New roles and therapeutic implications in cardiac fibrosis

Liu, Zhiyan; Song, Kai; Tu, Bin; Li, Lin; Sun, He; Zhou, Yang; Li, Rui; Yan, Shuhua; Yang, Jingjing; Zhang, Ye; Zhao, Jin; Tao, Hui

doi:10.1016/j.redox.2023.102820

Cited by 27 publications

(5 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While other research demonstrates that miRNA-29 upregulation is associated with cardiovascular diseases [18], in our study cohort a non-significant increase in its level in the group 2 and a significant increase in group 1 has been detected. Consistent with our findings, miRNA-29 has been considered to be protective against the accumulation of oxidative stress, and its rise can limit cardiac fibrosis [19]. Indeed, many investigations suggest that aberrant expression of miRNA-27 is associated with atherosclerosis, as well as angiogenesis, adipogenesis, inflammation, lipid metabolism, oxidative stress, insulin resistance and type 2 diabetes [20].…”

Section: Introductionsupporting

confidence: 90%

MicroRNAs and Oxidative Stress Markers as Additional Diagnostic Criteria for Coronary Heart Disease

Marchenko,

Rudenko,

Krasnienkov

2024

ujcvs

View full text Add to dashboard Cite

The aim. To examine the significance of microribonucleic acids (miRNAs) and oxidative stress markers in predicting the onset of atherosclerosis and the connection between oxidative stress levels and miRNAs in individuals with coronary heart disease. Materials and methods. Initially, 40 patients were divided as follows: 10 subjects without any lesions in coronary arteries (group 0), 4 patients with non-stenotic atherosclerosis (group 1), and 26 patients with significant multivessel atherosclerotic lesions (group 2). Various biochemical parameters were analyzed, including miRNA expression levels and common oxidative stress markers. Results. The groups were comparable in terms of the patients’ age, but there was unequal distribution of males and females in the angio-groups as per Fisher’s exact test. We also analyzed the data separately for females, but no significant difference was found. There were significant differences in miRNA-122 levels, N-terminal prohormone of brain natriuretic peptide levels, lipid profiles, and oxidative stress markers between group 0 and groups with atherosclerotic lesions. Specifically, miRNA-122 levels were elevated in group 0, along with N-terminal prohormone of brain natriuretic peptide, triglycerides, ratio of triglycerides to high-density lipoprotein cholesterol, and oxidative stress markers. Conversely, compared to group 0, total cholesterol, high-density lipoprotein cholesterol, bilirubin, and specific glutathione levels decreased in patients with coronary lesions. Conclusions. The study demonstrated the potential of miRNAs, particularly miRNA-122, as predictive biomarkers for atherosclerosis. Further research with larger cohorts is warranted to validate these findings and explore additional miRNA candidates and therapeutic interventions for cardiovascular diseases.

show abstract

Section: Introductionsupporting

confidence: 90%

MicroRNAs and Oxidative Stress Markers as Additional Diagnostic Criteria for Coronary Heart Disease

Marchenko,

Rudenko,

Krasnienkov

2024

ujcvs

View full text Add to dashboard Cite

show abstract

“…Third, epigenetic modifications and PTMs of targets that induce or inhibit ferroptosis have been identified, and dysregulated epigenetic modifications and PTMs can be feasibly targeted by small molecule compounds. Epigenetic drugs have exhibited viable therapeutic potential for NSDs, 607 – 610 CVDs, 611 – 615 liver diseases, 616 , 617 lung diseases, 618 – 620 and kidney diseases 621 – 623 in preclinical and clinical trials. Epigenetic drugs targeting epigenetic regulators through modulation of epigenetic mechanisms have been applied and clinically translated for the treatment of hematological malignancies, greatly contributing to the development of antitumor drugs.…”

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Wang,

Hu,

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Ferroptosis, a unique modality of cell death with mechanistic and morphological differences from other cell death modes, plays a pivotal role in regulating tumorigenesis and offers a new opportunity for modulating anticancer drug resistance. Aberrant epigenetic modifications and posttranslational modifications (PTMs) promote anticancer drug resistance, cancer progression, and metastasis. Accumulating studies indicate that epigenetic modifications can transcriptionally and translationally determine cancer cell vulnerability to ferroptosis and that ferroptosis functions as a driver in nervous system diseases (NSDs), cardiovascular diseases (CVDs), liver diseases, lung diseases, and kidney diseases. In this review, we first summarize the core molecular mechanisms of ferroptosis. Then, the roles of epigenetic processes, including histone PTMs, DNA methylation, and noncoding RNA regulation and PTMs, such as phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, and ADP-ribosylation, are concisely discussed. The roles of epigenetic modifications and PTMs in ferroptosis regulation in the genesis of diseases, including cancers, NSD, CVDs, liver diseases, lung diseases, and kidney diseases, as well as the application of epigenetic and PTM modulators in the therapy of these diseases, are then discussed in detail. Elucidating the mechanisms of ferroptosis regulation mediated by epigenetic modifications and PTMs in cancer and other diseases will facilitate the development of promising combination therapeutic regimens containing epigenetic or PTM-targeting agents and ferroptosis inducers that can be used to overcome chemotherapeutic resistance in cancer and could be used to prevent other diseases. In addition, these mechanisms highlight potential therapeutic approaches to overcome chemoresistance in cancer or halt the genesis of other diseases.

show abstract

“…This intricate interplay hastens the progression of metabolic diseases and highlights the critical need for research into comprehensive therapeutic strategies that address these underlying molecular pathways. For example, the modulation of pathways like the Nrf2 signaling pathway, which controls the expression of antioxidant proteins, and the NF-κB pathway, which regulates inflammation, could provide targeted intervention strategies for restoring metabolic and cardiovascular balance [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Metabolic Diseases: The Role of Nutraceuticals in Modulating Oxidative Stress and Inflammation

Dama,

Shpati,

Daliu

et al. 2024

Nutrients

View full text Add to dashboard Cite

The escalating prevalence of metabolic and cardiometabolic disorders, often characterized by oxidative stress and chronic inflammation, poses significant health challenges globally. As the traditional therapeutic approaches may sometimes fall short in managing these health conditions, attention is growing toward nutraceuticals worldwide; with compounds being obtained from natural sources with potential therapeutic beneficial effects being shown to potentially support and, in some cases, replace pharmacological treatments, especially for individuals who do not qualify for conventional pharmacological treatments. This review delves into the burgeoning field of nutraceutical-based pharmacological modulation as a promising strategy for attenuating oxidative stress and inflammation in metabolic and cardiometabolic disorders. Drawing from an extensive body of research, the review showcases various nutraceutical agents, such as polyphenols, omega-3 fatty acids, and antioxidants, which exhibit antioxidative and anti-inflammatory properties. All these can be classified as novel nutraceutical-based drugs that are capable of regulating pathways to mitigate oxidative-stress- and inflammation-associated metabolic diseases. By exploring the mechanisms through which nutraceuticals interact with oxidative stress pathways and immune responses, this review highlights their potential to restore redox balance and temper chronic inflammation. Additionally, the challenges and prospects of nutraceutical-based interventions are discussed, encompassing bioavailability enhancement, personalized treatment approaches, and clinical translation. Through a comprehensive analysis of the latest scientific reports, this article underscores the potential of nutraceutical-based pharmacological treatment modulation as a novel avenue to fight oxidative stress and inflammation in the complex landscape of metabolic disorders, particularly accentuating their impact on cardiovascular health.

show abstract

Crosstalk between oxidative stress and epigenetic marks: New roles and therapeutic implications in cardiac fibrosis

Cited by 27 publications

References 74 publications

MicroRNAs and Oxidative Stress Markers as Additional Diagnostic Criteria for Coronary Heart Disease

MicroRNAs and Oxidative Stress Markers as Additional Diagnostic Criteria for Coronary Heart Disease

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Targeting Metabolic Diseases: The Role of Nutraceuticals in Modulating Oxidative Stress and Inflammation

Contact Info

Product

Resources

About